Lucian pop

Dr. Lucian pop

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2019 in Journal of Medicine and Life
Verified
Journal Article
Open access
ISIoan Dumitru Suciu
Ioan Dumitru Suciu
OTOana Daniela Toader
Oana Daniela Toader
SGSlavyana Galeva
Slavyana Galeva
LPLucian pop
Lucian pop
The last decade has seen incredible advances in the genetic era, in next-generation sequencing of cell-free DNA in the maternal plasma, detecting abnormal fetal chromosomes. Non-invasive prenatal testing (NIPT) has showed increased sensitivity and specificity for Down syndrome superior to any other screening test. Technical advances have made possible the detection of other conditions which does not necessarily mean clinical benefit for the patient. Private laboratories have added multiple conditions in the panel of NIPT, but some of these abnormalities are so rare, that their prevalence is not even clear. Data regarding clinical performance of extended NIPT is lacking. Implementation of such a test has to be carefully weighed, and not only the benefits but also the harm should be taken into account.

2 December 2019 in The Journal of Maternal-Fetal & Neonatal Medicine
Verified
Journal Article
Closed access
ISIoan Suciu
Ioan Suciu
SGSlavyana Galeva
Slavyana Galeva
SASamira Abdel Azim
Samira Abdel Azim
LPLucian pop
Lucian pop
OTOana Toader
Oana Toader
Background: The introduction of cell-free DNA into clinical practice has changed the screening approach. Healthcare professionals and future parents tend to overestimate NIPT (noninvasive prenatal testing) capabilities despite its relatively high cost and limited information. Objective: In this review, our aim was to survey how various countries have introduced contingent screening models and to discuss the advantages and disadvantages of the combined screening test and the use of NIPT. Data source: The Web of Science, PubMed database and institutional websites were searched for information regarding screening approaches and the implementation in different countries. Results: There are nine countries and regions that have already approved contingent screening test, while others (eg Australia) are discussing the implementation of contingent screening versus universal use of NIPT. There are several recent meta-analyses debating whether to use NIPT for universal screening for trisomies and other fetal conditions. Conclusions: NIPT is a reasonable option as an advanced screening test for trisomy 21,18 and 13 only. Introducing screening by NIPT instead of a first-trimester screening will cause the loss of other valuable information including accurate dating of pregnancy, diagnosing major structural fetal abnormalities and multiple pregnancies at an early gestational age. Additionally, the opportunity to screen for early preeclampsia will be lost. Currently, the price for NIPT is still high adding extra strain on publicly funded health systems.

16 November 2021 in Medicina
Verified
Journal Article
Open access
PDF file
Tiberiu Augustin GeorgescuTiberiu Augustin Georgescu
Tiberiu Augustin Georgescu
VRViorica Radoi
Viorica Radoi
MRMicaela Radulescu
Micaela Radulescu
AIAurora Ilian
Aurora Ilian
OTOana Daniela Toader
Oana Daniela Toader
Nicolae BacalbaşaNicolae Bacalbaşa
Nicolae Bacalbaşa
Tracheal atresia is an extremely rare condition whereby a partial or total obstruction of the trachea is seen. It is almost always lethal, with just a handful of cases that ended with a good outcome. In this study we report on a 15-week male fetus, diagnosed with hyperechogenic lungs, midline heart position and inverted diaphragm. Sonographic findings suggest congenital High Airway Obstruction Syndrome (CHAOS) An ultrasound scan and fetal MRI were not able to point out the exact obstruction level. In spite of extensive counselling, the parents opted to carry on with the pregnancy. Fetal demise was noted on a scan at 19 weeks gestation. After the elective termination of pregnancy, a post-mortem examination showed partial tracheal atresia with no other anomalies. Despite technological progress in CHAOS syndrome, a precise diagnosis and accurate prognosis remain elusive.

1 April 2022 in Journal of Medicine and Life
Verified
Journal Article
Open access
TGTiberiu Georgescu
Tiberiu Georgescu
OIOlivia Ionescu
Olivia Ionescu
OTOana Daniela Toader
Oana Daniela Toader
NBNicolae Bacalbasa
Nicolae Bacalbasa
LPLucian pop
Lucian pop
Fibular hemimelia is defined as a partial or complete absence of the fibula. Alongside fibular deformities, there is a wide spectrum of anomalies, foot deformities, and absent rays. A literature review showed only a handful of cases of prenatal diagnosis of fibular hemimelia. It is a rare disorder that might be isolated or associated with visceral anomalies.

1 October 2019 in Journal of Medicine and Life
Verified
Journal Article
Open access
LPLucian pop
Lucian pop
ISIoan Dumitru Suciu
Ioan Dumitru Suciu
OIOlivia Ionescu
Olivia Ionescu
PIParis Ionescu
Paris Ionescu
OTOana Daniela Toader
Oana Daniela Toader
Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete pathologic response in the breast and in the axilla. The purpose of this review is to outline the efficacy of the dual blockade with Trastuzumab and Pertuzumab in the neoadjuvant treatment of high-risk Her-2 positive breast cancer. Electronic databases (Pubmed, Medline, and Cochrane Database of Systematic Reviews) were searched for English- and German-language studies, which were published in the last ten years. The search has been focused on neoadjuvant clinical trials as well as on the data presented in the abstracts published at the San Antonio Breast Cancer Symposium as well as at the annual meeting of the American Society of Clinical Oncology. The results reported in the published clinical trials demonstrated a higher pathologic complete response rate in breast and lymph nodes after using targeted therapy with two anti-Her-2/neu agents - Trastuzumab and Pertuzumab in combination with neoadjuvant chemotherapy for early-stage Her-2/neu positive breast cancers. The pathologic complete response rate is the most important prognostic marker in Her-2/neu positive tumors, a higher pathologic complete response rate being demonstrated to be associated with a better survival outcome in terms of higher overall survival and disease-free survival rates.

1 January 2021 in Journal of Medicine and Life
Verified
Journal Article
Open access
LPLucian pop
Lucian pop
ISIoan Suciu
Ioan Suciu
OIOlivia Ionescu
Olivia Ionescu
NBNicolae Bacalbasa
Nicolae Bacalbasa
PIParis Ionescu
Paris Ionescu
The use of the PARP inhibitors (PARPi) in the treatment of breast cancer (BC) with germine mutations has evolved over the years, and further research has been done in order to broaden the horizon of this treatment strategy. Therefore the aim of this paper is to review the efficiency of PARPi in the treatment of BRCA 1/2-mutated locally advanced and metastatic Her-2/net negative BC mentioning their side effects, mechanism of resistance and future directions. Inhibition of PARP transforms single-strand breaks into double-strand breaks (DBS), the accumulation of the latter causing cell death (cell apoptosis). The Olympia AD phase III trial demonstrated a statistically significant progression-free survival rate (PFS) when using the PARPi olaparib in metastatic BC with germline BRCA1/2 mutations without any benefit of the overall survival rate. PARPi therapy is associated with acceptable responsive rates and progression-free survival rates in locally advanced and metastatic BRCA1/2 associated BC through mechanisms that enhance and increase the sensitivity to chemotherapeutic or target agents as they induce a synthetic lethality and cell apoptosis. The side effects are not significant, the most adverse effects being related to the hematological and gastrointestinal systems. Olaparib is currently approved in the first-line treatment of BRCA1/2 mutated Her-2/neu negative metastatic BC at an oral dose of 300 mg twice daily, while Talazoparib represents a category one recommendation in locally advanced and metastatic Her-2/neu negative BC in women with central nervous system metastases.